Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage 2 Hypertension Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
View directory record Official record
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

NCT01195662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

NCT04712669
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT02129673
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops
Drug
Lead sponsor
ViSci Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Selonsertib in Adults With Pulmonary Arterial Hypertension

NCT02234141
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Selonsertib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

NCT05314439
View directory record Official record
Conditions
Hypertension
Interventions
ION904, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cypress, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

NCT04091087
View directory record Official record
Conditions
Stasis Dermatitis
Interventions
crisaborole ointment, vehicle ointment
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
El Segundo, California • Lafayette, California • South San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Results available

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

NCT00770861
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Buena Park, California • Chino, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

NCT03657550
View directory record Official record
Conditions
Hypertension
Interventions
Levamlodipine, Amlodipine, Amlodipine, Levamlodipine
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Results available

Nebivolol in Patients With Systolic Stage 2 Hypertension

NCT01057251
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Foley, Alabama • Montgomery, Alabama • Chino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

NCT00797316
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2011 · Synced Oct 30, 2026, 11:31 AM EDT
Active, not recruiting Phase 3 Interventional

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

NCT05983250
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125
View directory record Official record
Conditions
JNC 7 Stage 1 or 2 Hypertension
Interventions
Nebivolol I, Nebivolol II, Baseline Washout Phase
Drug · Other
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Not applicable Interventional

Weight Inclusive and Adaptive Strategies to Enhance Cardiometabolic Health in Black Adults

NCT06284681
View directory record Official record
Conditions
Obesity, Prehypertension, Hypertension, PreDiabetes, Type 2 Diabetes, Dyslipidemia
Interventions
Weight-focused health coaching, Weight-neutral health coaching, Intensify lifestyle approach, Augment with enhanced medical management
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
Lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

NCT00430638
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide, if necessary, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100
View directory record Official record
Conditions
Stage 2 Diastolic Hypertension
Interventions
nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
89
States / cities
Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 4 Interventional

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

NCT00185068
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
16
States / cities
Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2005 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Not applicable Interventional

Cut Your Pressure Too: The Altadena Barbershop Blood Pressure Study, Phase 2 (Intervention Pilot Study)

NCT02198144
View directory record Official record
Conditions
Hypertension
Interventions
barbershop-based BP measurement
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 30, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

NCT04083222
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Tustin, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 30, 2026, 11:31 AM EDT